In separate decisions, regulatory authorities in the US and Europe have paved the way for the introduction of two new medicines for different blood cancers – substantially increasing the treatment options for patients with a number of rare cancers. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News
